AID Logo

Home >> Directory >> Anna Wald, MD, MPH

Faculty

Contact Information

Anna Wald, MD, MPH

  • Professor, Division of Allergy and Infectious Diseases, Department of Medicine and Departments Epidemiology and Laboratory Medicine
  • University of Washington
  • Member, Vaccine and Infectious Diseases Division
  • Fred Hutchinson Cancer Research Center

Current research centers on the epidemiology, natural history, and immunobiology of herpes simplex virus infection in immunocompetent and immunocompromised hosts. The goals of the studies are to

  1. characterize the biology and epidemiology of HSV acquisition and transmission;
  2. investigate the immunopathology of mucosal and ganglionic HSV infection,
  3. develop strategies for prevention of HSV transmission from women to neonates at birth and between sexual partners;
  4. understand the biology of interactions between HIV and HSV-2.

Additional studies focus the role of chronic viral infections, especially CMV, in immunosenescence in healthy and immunocompromised host. Several ongoing studies and clinical trials address the vaccine development for HSV-2. Main collaborators include David Koelle, Christine Johnston, Joshua Schiffer, Jia Zhu, Michael Boeckh and Larry Corey; also collaborating with Corey Casper on studies of epidemiology and pathobiology of HHV-8 infection at Uganda Cancer Institute in Kampala, Uganda. Other interests include vaccine studies (influenza, HSV, CMV) and study design. An ongoing cohort of girls who have not initiated sexual activity is enrolled in Thika, Kenya, to evaluate the immunologic changes in the genital tract that occur with sexual debut and HSV-2 acquisition.

All studies listed above offer opportunities for fellows.


Selected Publications


Melvin AJ, Mohan KM, Schiffer JT, Drolette LM, Magaret A, Corey L, Wald A. Plasma and CSF herpes simplex virus levels at diagnosis and outcome of neonatal infection. J Pediatr in press.
PubMed Abstract

Rajagopal S#, Magaret A, Mugo N, Wald A.  Incidence of herpes simplex virus type 2 infections in Africa: a systematic review.  Open Forum Infect Dis (Summer 2014) 1 (2): doi: 10.1093/ofid/ofu043
PubMed Abstract

Delaney S#, Gardella C, Saracino M, Magaret A, Wald A. Seroprevalence of herpes simplex virus type 1 and 2 among pregnant women, 1989-2010.  JAMA (Research Letter) 2014 Aug 20;312(7):746-8.
PubMed Abstract

Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A. Helicase-Primase Inhibitor Pritelivir for Herpes Simplex Virus 2 Infection. N Eng J Med 2014;370:201-210.
PubMed Abstract

Perti T, Saracino M, Baeten J, Johnston C, Diem K, Ochbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A. High-dose valacyclovir decreases plasma HIV-1 levels more than standard dose acyclovir in HIV-1, HSV-2 positive persons: a randomized, crossover trial. J Acquir Immune Dfic Syndr. 2013; 63(2): 201-8.
PubMed Abstract

Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. PMID: 22225814.
Lancet Abstract

to top